Identification of chemoresistance-associated microRNAs and hub genes in breast cancer using bioinformatics analysis

Author(s):  
Ming Wu ◽  
Yujie Zhao ◽  
Nanxi Peng ◽  
Zuo Tao ◽  
Bo Chen
Author(s):  
Haoxuan Jin ◽  
Xiaoyan Huang ◽  
Kang Shao ◽  
Guibo Li ◽  
Jian Wang ◽  
...  

Gland Surgery ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 799-806
Author(s):  
Li-Min Wei ◽  
Xin-Yang Li ◽  
Zi-Ming Wang ◽  
Yu-Kun Wang ◽  
Ge Yao ◽  
...  

Gene ◽  
2021 ◽  
pp. 146016
Author(s):  
Bhavjot Kaur ◽  
Yahya Mukhlis ◽  
Jagadish Natesh ◽  
Dhanamjai Penta ◽  
Syed Musthapa Meeran

2021 ◽  
Vol 10 (5) ◽  
pp. 2399-2408
Author(s):  
Limin Wei ◽  
Yukun Wang ◽  
Dan Zhou ◽  
Xinyang Li ◽  
Ziming Wang ◽  
...  

PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e9946
Author(s):  
Mingqian Hao ◽  
Wencong Liu ◽  
Chuanbo Ding ◽  
Xiaojuan Peng ◽  
Yue Zhang ◽  
...  

Breast cancer is one of the most common malignant tumors among women worldwide and has a high morbidity and mortality. This research aimed to identify hub genes and small molecule drugs for breast cancer by integrated bioinformatics analysis. After downloading multiple gene expression datasets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database, 283 overlapping differentially expressed genes (DEGs) significantly enriched in different cancer-related functions and pathways were obtained using LIMMA, VennDiagram and ClusterProfiler packages of R. We then analyzed the topology of protein–protein interaction (PPI) network with overlapping DEGs and further obtained six hub genes (RRM2, CDC20, CCNB2, BUB1B, CDK1, and CCNA2) from the network via STRING and Cytoscape. Subsequently, we conducted genes expression verification, genetic alterations evaluation, immune infiltration prediction, clinicopathological parameters analysis, identification of transcriptional and post-transcriptional regulatory molecules, and survival analysis for these hub genes. Meanwhile, 29 possible drug candidates (e.g., Cladribine, Gallium nitrate, Alvocidib, 1β-hydroxyalantolactone, Berberine hydrochloride, Nitidine chloride) were identified from the DGIdb database and the GSE85871 dataset. In addition, some transcription factors and miRNAs (e.g., E2F1, PTTG1, TP53, ZBTB16, hsa-miR-130a-3p, hsa-miR-204-5p) targeting hub genes were identified as key regulators in the progression of breast cancer. In conclusion, our study identified six hub genes and 29 potential drug candidates for breast cancer. These findings may advance understanding regarding the diagnosis, prognosis and treatment of breast cancer.


Sign in / Sign up

Export Citation Format

Share Document